Anecortave Acetate
Modify Date: 2024-01-04 23:27:30
Anecortave Acetate structure
|
Common Name | Anecortave Acetate | ||
|---|---|---|---|---|
| CAS Number | 7753-60-8 | Molecular Weight | 386.48100 | |
| Density | 1.23g/cm3 | Boiling Point | 551.8ºC at 760 mmHg | |
| Molecular Formula | C23H30O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 188.4ºC | |
Use of Anecortave AcetateAnecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2]. |
| Name | [2-[(8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate |
|---|---|
| Synonym | More Synonyms |
| Description | Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PAI-1[2] |
| In Vivo | Anecortave acetate (5 μl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels[2]. Animal Model: Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)[2] Dosage: 5 μl of a 10% suspension of Anecortave acetate Administration: Injected into eyes Result: significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels. Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection. |
| Density | 1.23g/cm3 |
|---|---|
| Boiling Point | 551.8ºC at 760 mmHg |
| Molecular Formula | C23H30O5 |
| Molecular Weight | 386.48100 |
| Flash Point | 188.4ºC |
| Exact Mass | 386.20900 |
| PSA | 80.67000 |
| LogP | 3.30170 |
| Index of Refraction | 1.572 |
| Precursor 8 | |
|---|---|
| DownStream 5 | |
CAS#:50-03-3
CAS#:75868-48-3
CAS#:63973-98-8
CAS#:3800-41-7![(8S,9R,10S,13S,14S,17R)-17-(2-acetoxyacetyl)-9-chloro-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl nicotinate Structure](https://image.chemsrc.com/caspic/279/108674-98-2.png)
CAS#:108674-98-2
CAS#:113862-93-4
CAS#:566-35-8
CAS#:428516-04-5
CAS#:514-36-3
CAS#:2398-99-4
CAS#:10184-70-0
CAS#:10072-97-6
CAS#:127-31-1| 2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| 21-Acetoxy-17-hydroxy-pregna-4,9(11)-dien-3,20-dion |
| Retaane |
| 21-acetoxy-17-hydroxy-pregna-4,9(11)-diene-3,20-dione |
| AL-3789 |
| 2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate |
| Anecortave |
| Anecortave acetate |
| Retaane suspension |